Previous 10 | Next 10 |
Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candidates with one showing the most favorable profile The company plans to conduct dose optimization studies with a focus on the preferred formu...
2024-07-10 07:09:08 ET More on Evotec SE, Evotec SE, etc. The Next Paxlovid Pfizer: Buy This Big Yielder On The Strong Pipeline Pfizer: The Inflection Point Is Here Pfizer R&D head Mikael Dolsten to depart Executive reshuffles: NIO, Pfizer and Spi...
2024-07-10 07:00:08 ET Carter Gould from Barclays issued a price target of $30.00 for PFE on 2024-07-10 05:53:00. The adjusted price target was set to $30.00. At the time of the announcement, PFE was trading at $27.72. The overall price target consensus is at $55.44 with...
2024-07-09 14:50:00 ET Summary Paxlovid treatment consists, each dose, of three pills: two of nirmatrelvir and one of ritonavir. Ibuzatrelvir fits right into the active site of the coronavirus main protease. So as long as we have the current coronvirus with us - and it looks t...
2024-07-09 07:44:38 ET Summary Pfizer's cash flow from operations in 2022 was $29.267 billion, driven by COVID-19 vaccine and Paxlovid sales, but dropped to $8.7 billion in 2023. Despite revenue loss from COVID-19 drugs, the Company has a strong drug pipeline and scale advantage o...
2024-07-09 07:03:43 ET More on Pfizer Pfizer: The Inflection Point Is Here Pfizer: It Could Be A Bargain Wall Street Lunch: Pfizer Looks To Take Next Step In Weight-Loss Drugs Executive reshuffles: NIO, Pfizer and Spirit Airlines in focus COVID infect...
Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and President, Pfizer Research & Development, who will depart the company after a more than 15-year stellar career. This p...
2024-07-08 12:30:52 ET Summary Eli Lilly and Company is set to acquire Morphic Holding for $3.2bn. Morphic is focused on autoimmune disease drugs. Morphic's MORF-057 has a similar MoA to Takeda's ~$5bn per annum selling drug entyvio, but it is orally available, unlike the injectab...
2024-07-08 10:53:56 ET Summary Pfizer's recent financial performance and Wall Street analysts' expectations around the upcoming quarterly earnings release suggest that we are currently at an inflection point. The company's current pipeline of new product developments looks promisi...
2024-07-08 10:00:00 ET Pfizer (NYSE: PFE) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has it paid a dividend like clockwork for decades, the company ha...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...